B-SOFT Co (300451) Fair Value & Analysis
Healthcare · CN · Market cap 5.5B CNY
Fair value as of: Jul 9, 2026
From 1 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from ¥11.65 to ¥1.02 (−91.2%) since Jun 24, 2026. Share price −15.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥3.14 – ¥6.63 · fair‑value band ¥0.6800 – ¥1.28 · the ¥3.14 price screens above the ¥1.02 fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
B-SOFT Co (300451) currently trades at ¥3.14, while our model-based Fair Value estimate is ¥1.02 — implying the stock looks roughly 67.5% overvalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, B-SOFT Co generated revenue of 959M CNY at a net margin of -48.6%. Revenue declined 32.0% year over year. It earns a return on equity of -10.7%. The balance sheet holds a net cash position of 962M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥0.6800 (bear case) to ¥1.28 (bull case); at ¥3.14, the current price sits above that range. The share trades about 55% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -39% fair-value upside — at -68%, 300451 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
B-SOFT Co.,Ltd. operates in the healthcare information technology industry in China. The company offers Huikang·Yunshu Intelligent Body, a medical AI agent of Huikang. It also provides outpatient registration and appointment center, medical technology appointment center, inpatient and outpatient services, and hospital cloud platform; and big data and artificial intelligence, hospital-wide medical-technical integration, mobile intelligent healthcare, hospital multidisciplinary consultation, clinical decision, b-soft overall solution for epidemic prevention and control, and Hi-HIS. In addition, the company offers management decision support, intelligent comprehensive management, hospital medical insurance risk management, performance management, intelligent management application, refined management system for low value consumables, consumables traceability management system, and consumables trading supervision and drug trade supervision platform; and intelligent IoT, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
B-SOFT Co reported revenue of ¥1.1B in FY2025 versus ¥1.9B in FY2021, a compound −13.7%/yr. Reported net income was −¥402M in FY2025.
Is 300451 fairly valued? → Check now
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $172.61 | $104.16 | -40% |
| Pro Medicus Limited PME | A$165.64 | A$28.02 | -83% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $89.72 | $54.47 | -39% |
| M3, Inc MTHRY | $5.03 | $7.44 | +48% |
| Hinge Health, Inc HNGE | $68.85 | $78.43 | +14% |
| Ping An Healthcare and Technology Company PANHF | $0.9000 | $0.5700 | -37% |
| 10x Genomics, Inc TXG | $29.11 | $17.86 | -39% |
| XtalPi Holdings 2228 | HK$7.48 | HK$1.03 | -86% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is B-SOFT Co (300451) undervalued?
What is the fair value of 300451?
What is the quality score of 300451?
What is the revenue of B-SOFT Co (300451)?
What is the net profit margin of 300451?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.